Janus Henderson Group PLC Has $9.61 Million Stock Holdings in PROCEPT BioRobotics Corporation $PRCT

Janus Henderson Group PLC raised its position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 12.7% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 384,246 shares of the company’s stock after buying an additional 43,405 shares during the period. Janus Henderson Group PLC’s holdings in PROCEPT BioRobotics were worth $9,610,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Amundi raised its position in shares of PROCEPT BioRobotics by 16.2% during the first quarter. Amundi now owns 23,394 shares of the company’s stock worth $585,000 after acquiring an additional 3,260 shares during the last quarter. California State Teachers Retirement System boosted its holdings in PROCEPT BioRobotics by 34.3% in the first quarter. California State Teachers Retirement System now owns 70,184 shares of the company’s stock valued at $1,755,000 after acquiring an additional 17,937 shares during the last quarter. Royal Bank of Canada increased its position in PROCEPT BioRobotics by 167.1% in the first quarter. Royal Bank of Canada now owns 38,962 shares of the company’s stock worth $975,000 after purchasing an additional 24,375 shares during the period. CPMG Inc acquired a new stake in PROCEPT BioRobotics in the first quarter worth about $10,661,000. Finally, Quantinno Capital Management LP acquired a new stake in PROCEPT BioRobotics in the first quarter worth about $1,693,000. 89.46% of the stock is owned by institutional investors and hedge funds.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Second-quarter revenue rose 19.3% year over year to $94.5 million, exceeding analysts’ $92.77 million estimate. The result suggests continued demand for PROCEPT’s urology-focused robotic systems despite broader concerns about customer inventory. PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management forecast fiscal 2026 revenue of $390 million to $410 million, a range that broadly brackets the $397.2 million consensus estimate and may have eased concerns about a sharp near-term slowdown.
• Neutral Sentiment: The company reported an adjusted loss of $0.47 per share, narrowly missing the $0.46 consensus estimate and worsening from a $0.35 loss in the year-ago quarter. PROCEPT remains unprofitable, with analysts expecting a full-year loss. PROCEPT BioRobotics Reports Q2 Loss, Beats Revenue Estimates
• Negative Sentiment: Wells Fargo downgraded PROCEPT from “overweight” to “equal weight” and set a $19 price target, signaling limited upside at recent trading levels. Wells Fargo downgrade report
• Negative Sentiment: Multiple law firms publicized a securities-fraud class action covering investors who purchased PRCT shares from February 28, 2024, through February 25, 2026. The allegations include material misstatements about product demand, excess customer inventory, and late-quarter bulk discounts that may have overstated recurring-revenue trends. Investors seeking lead-plaintiff status generally face a September 22, 2026 deadline. Levi & Korsinsky PROCEPT class action alert

Wall Street Analyst Weigh In

A number of research analysts have issued reports on PRCT shares. William Blair downgraded shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Robert W. Baird set a $20.00 price target on shares of PROCEPT BioRobotics in a research report on Wednesday. Truist Financial set a $21.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Friday, July 17th. Finally, UBS Group lowered shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 target price for the company. in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, PROCEPT BioRobotics currently has an average rating of “Hold” and an average target price of $28.00.

PROCEPT BioRobotics Trading Up 5.8%

NASDAQ:PRCT opened at $19.34 on Thursday. The company has a current ratio of 6.73, a quick ratio of 5.51 and a debt-to-equity ratio of 0.15. PROCEPT BioRobotics Corporation has a 1-year low of $16.67 and a 1-year high of $47.97. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -9.97 and a beta of 0.89. The business’s 50-day moving average price is $21.85 and its two-hundred day moving average price is $24.89.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The company had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.10% and a negative net margin of 32.53%.PROCEPT BioRobotics’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.35) earnings per share. On average, equities analysts expect that PROCEPT BioRobotics Corporation will post -1.53 earnings per share for the current year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.